Author: Kathryn Atkins

Reassessing COVID-19 Precautions in 2023

September 27, 2023

“The balance between appropriate precautions and the harm of social isolation always requires a thorough appraisal.” BUFFALO, NY- September 27, 2023 – A new editorial paper was published in Oncotarget's… read more

Figure 4: Visual representation of the datasets used in this study on EC and PCOS

Oncotarget

Four Novel Receptors May Link Endometrial Cancer to PCOS

September 25, 2023

“These findings hold significant promise for improving our understanding of mechanistic pathways leading to EC in PCOS.” BUFFALO, NY- September 25, 2023 – A new research paper was published in… read more

Oncotarget

DPP4 Inhibitors for Target Therapy Resistance in Renal Cell Carcinoma

September 20, 2023

“[...] we demonstrated that DPP4 inhibition increased sunitinib efficacy in DPP4-high RCC spheroids and DPP4 was upregulated in sunitinib-resistant RCC cells.” BUFFALO, NY- September 20, 2023 – A new editorial… read more

Figure 1: (A) Sliced fresh tumor samples were cultured in 96-well plates and viability was measured with PrestoBlue daily for 5 days. X-axis is days, and Y-axis is proportion of viability. (B) Sliced fresh tumor samples were embedded with paraffin, and tissue sections were stained with hematoxylin and eosin (H&E), Masson trichrome, αSMA, CD34 and Ki-67 antibodies.

Oncotarget

Real-Time Live Tissue Sensitivity Assay for Pancreatic Adenocarcinoma

September 19, 2023

“This approach may allow clinicians to select the most effective therapeutic agents with real time in patients with pancreatic adenocarcinoma.” BUFFALO, NY- September 19, 2023 – A new research paper… read more

Oncotarget

Systemic Treatment for Brain Metastasis in HER2-Positive Advanced Breast Cancer

September 13, 2023

“With these new drugs now available in clinical practice, we expect HER2+/HER2-low BC patients with BMs to live longer and to live better.” BUFFALO, NY- September 13, 2023 – A… read more

Oncotarget

Updates: MET Targeted Therapy for EXON 14 Mutations in Lung Cancer

September 11, 2023

“The future looks bright for patients with MET mutations and NSCLC.” BUFFALO, NY- September 11, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on May 26,… read more

Oncotarget

A Macrophage is a Macrophage is a Macrophage—in Metastasis

August 23, 2023

“We hope that these results will inform future attempts at anti-macrophage therapy and lead to better outcomes for patients in the not-too-distant future.” BUFFALO, NY- August 23, 2023 – A… read more

Oncotarget

Aggressive Luminal Breast Cancer: Are Cis-Spliced Fusion Proteins Pathological?

August 21, 2023

“Our findings may provide a useful therapeutic approach for treating breast cancer patients who may suffer from early relapse and intrinsic resistance.” BUFFALO, NY- August 21, 2023 – A new… read more

Figure 1: Glutamine metabolism effect in tumor microenvironment cells.

Oncotarget

Inhibiting Glutamine Metabolism Impacts Tumor Cells or the Microenvironment?

August 16, 2023

“These new findings evidence the necessity of more research in Gln metabolism to define the best therapeutic strategies for cancer patients.” BUFFALO, NY- August 16, 2023 – A new editorial… read more

Figure 1: Tumor intrinsic and extrinsic factors in the periphery that can serve as proxies of tumor burden. Peripheral surrogates

Oncotarget

Peripheral Surrogates of Tumor Burden to Guide Therapeutic Strategies for HPV-Associated Malignancies

August 14, 2023

“We discuss existing clinical data on these surrogates of tumor burden and their potential in evaluating efficacy of immunotherapy in HPV-associated malignancies.” BUFFALO, NY- August 14, 2023 – A new… read more